Efficacy of single‐agent immunosuppressive regimens in a murine model of vascularized composite allotransplantation. (12th May 2020)
- Record Type:
- Journal Article
- Title:
- Efficacy of single‐agent immunosuppressive regimens in a murine model of vascularized composite allotransplantation. (12th May 2020)
- Main Title:
- Efficacy of single‐agent immunosuppressive regimens in a murine model of vascularized composite allotransplantation
- Authors:
- Guo, Yinan
Messner, Franka
Etra, Joanna W.
Beck, Sarah E.
Kalsi, Richa
Furtmüller, Georg J.
Schneeberger, Stefan
Chol Oh, Byoung
Brandacher, Gerald - Abstract:
- Summary: We herein investigate the safety and efficacy of single‐agent anti‐rejection regimens in a mouse vascularized composite allotransplantation (VCA) model. Orthotopic hind‐limb transplantations (Balb/c → C57BL/6) were performed using 6‐ to 8‐week‐old mice. A thirty‐day regimen of either rapamycin, tacrolimus (both 1, 3, 5 mg/kg/day) or cyclosporine (25, 35, 50 mg/kg/day) was used. Primary endpoints were animal and graft survival, and secondary chimerism and regulatory T‐cell levels. For rapamycin and tacrolimus given at 1, 3, and 5 mg/kg/day, median graft survival time (MST) was 23 days (18–28 days), 30 days (23–30 days), and 30 d (30–30 days) and 14 days (13–18 days), 30 days (16–30 days), and 30 days (30–30 days), respectively. For cyclosporine dosed at 25 and 35 mg/kg/day, MST was 15 days (12–18 days) and 21 days (14–27 days). Toxicity from CsA 50 mg/kg led to 100% mortality. Mixed chimerism levels were higher in rapamycin‐treated animals than in tacrolimus‐treated recipients ( P = 0.029). Tacrolimus was superior in preventing leukocyte recruitment to the allograft. In murine VCA, no standardized immunosuppressive regimen exists, limiting comparability of outcomes and survival. Our data demonstrate that rapamycin and tacrolimus maintenance treatment at 5 mg/kg/day both yielded allograft survival (<grade 3 rejection) in all animals. Rapamycin displayed less toxicity and maintained mixed chimerism but was not as potent in controlling leukocyte recruitment comparedSummary: We herein investigate the safety and efficacy of single‐agent anti‐rejection regimens in a mouse vascularized composite allotransplantation (VCA) model. Orthotopic hind‐limb transplantations (Balb/c → C57BL/6) were performed using 6‐ to 8‐week‐old mice. A thirty‐day regimen of either rapamycin, tacrolimus (both 1, 3, 5 mg/kg/day) or cyclosporine (25, 35, 50 mg/kg/day) was used. Primary endpoints were animal and graft survival, and secondary chimerism and regulatory T‐cell levels. For rapamycin and tacrolimus given at 1, 3, and 5 mg/kg/day, median graft survival time (MST) was 23 days (18–28 days), 30 days (23–30 days), and 30 d (30–30 days) and 14 days (13–18 days), 30 days (16–30 days), and 30 days (30–30 days), respectively. For cyclosporine dosed at 25 and 35 mg/kg/day, MST was 15 days (12–18 days) and 21 days (14–27 days). Toxicity from CsA 50 mg/kg led to 100% mortality. Mixed chimerism levels were higher in rapamycin‐treated animals than in tacrolimus‐treated recipients ( P = 0.029). Tacrolimus was superior in preventing leukocyte recruitment to the allograft. In murine VCA, no standardized immunosuppressive regimen exists, limiting comparability of outcomes and survival. Our data demonstrate that rapamycin and tacrolimus maintenance treatment at 5 mg/kg/day both yielded allograft survival (<grade 3 rejection) in all animals. Rapamycin displayed less toxicity and maintained mixed chimerism but was not as potent in controlling leukocyte recruitment compared with tacrolimus. … (more)
- Is Part Of:
- Transplant international. Volume 33:Number 8(2020)
- Journal:
- Transplant international
- Issue:
- Volume 33:Number 8(2020)
- Issue Display:
- Volume 33, Issue 8 (2020)
- Year:
- 2020
- Volume:
- 33
- Issue:
- 8
- Issue Sort Value:
- 2020-0033-0008-0000
- Page Start:
- 948
- Page End:
- 957
- Publication Date:
- 2020-05-12
- Subjects:
- chimerism -- immunosuppression -- mouse -- solid organ transplantation -- tissue transplantation -- vascularized composite allotransplantation
Transplantation of organs, tissues, etc -- Periodicals
617.95405 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1432-2277/issues ↗
https://www.frontierspartnerships.org/journals/transplant-international ↗
http://www.springerlink.com/content/0934-0874 ↗ - DOI:
- 10.1111/tri.13618 ↗
- Languages:
- English
- ISSNs:
- 0934-0874
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9024.989000
British Library STI - ELD Digital store - Ingest File:
- 13679.xml